WUXI BIOLOGICS (CAYMAN) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.62 HKD | -4.68% |
|
-10.50% | -57.36% |
| Sales 2023 | 17.03B 2.35B 18.43B | Sales 2024 * | 18.32B 2.53B 19.82B | Capitalization | 48.61B 6.71B 52.59B |
|---|---|---|---|---|---|
| Net income 2023 | 3.4B 470M 3.68B | Net income 2024 * | 3.95B 546M 4.27B | EV / Sales 2023 | 6.35 x |
| Net cash position 2023 | 5.45B 753M 5.89B | Net cash position 2024 * | 7B 967M 7.58B | EV / Sales 2024 * | 2.27 x |
| P/E ratio 2023 |
34.9
x | P/E ratio 2024 * |
12.8
x | Employees | 12,740 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 85.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on WuXi Biologics (Cayman) Inc.
More recommendations
More press releases
More news
| 1 day | -4.68% | ||
| 1 week | -10.50% | ||
| Current month | -11.75% | ||
| 1 month | -14.50% | ||
| 3 months | -56.63% | ||
| 6 months | -73.35% | ||
| Current year | -57.36% |
1 week
12.50
14.00
1 month
12.5015.00
Current year
12.5033.40
1 year
12.5053.95
3 years
12.50148.00
5 years
12.50148.00
10 years
8.33148.00
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 52 | 11-05-31 |
Ming Tu
DFI | Director of Finance/CFO | 54 | 21-08-22 |
Gu Jijie
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jackson Tai
BRD | Director/Board Member | 73 | 23-05-05 |
William Keller
BRD | Director/Board Member | 75 | 17-05-16 |
Ge Li
CHM | Chairman | 56 | 10-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.62% | 2 M€ | -20.87% | - | |
| 4.23% | 3 M€ | -6.96% | - | |
| 3.58% | 1 M€ | -9.86% | - | |
| 2.95% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 12.62 | -4.68% | 49,290,530 |
| 24-04-18 | 13.24 | -0.60% | 24,367,050 |
| 24-04-17 | 13.32 | +2.15% | 31,720,450 |
| 24-04-16 | 13.04 | -3.98% | 36,049,270 |
| 24-04-15 | 13.58 | -2.30% | 19,957,600 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT
More quotes
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
11.66
CNY
Average target price
28.39
CNY
Spread / Average Target
+143.35%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -57.36% | 7.05B | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- 2269 Stock
